

# Covid Vaccine Hesitancy & Safety 2021





# 5 A's



Access: To support uptake, ensure ease of access including the convenience of the service, its location and clinic times.



Affordability: Removing any out of pocket costs for the vaccine and vaccination services strongly affects uptake [5]. Time itself is a cost barrier to vaccination/cost of travel and fear of job security can result in a 'reduced willingness'

Awareness: Practical knowledge about the vaccine recommendation and understanding about the groups recommended to have a vaccine improves uptake. Awareness needs to address barriers to understanding. To reduce inequities in vaccine uptake, consumers must have access to health resources that are comprehensible, culturally tailored and are appropriate for the consumer's health literacy skills [6].


Acceptance: Concerns about the safety and effectiveness of a vaccine (including adverse effects) and lack of confidence in vaccine benefits, can all affect uptake. A high perceived severity of a disease increases intention to vaccinate [7, 8]. Acceptance can also be affected by trust in providers, and for adults, formative childhood vaccination experiences [9].

Activation: This refers to the strategies that help people to act on good intentions and vaccinate - the final 'nudge' [4]. Effective strategies to activate include reminders via SMS, email/letter, or app. An opportunistic recommendation from a provider can also activate a person to be vaccinated.



## How do vaccines work?





A VACCINE is a tiny weakened non-dangerous fragment of the organism and includes parts of the antigen. It's enough that our body can learn to build the specific antibody. Then if the body encounters the real antigen later, as part of the real organism, it already knows how to defeat it.




## Astra Zeneca Vaccine



#### A Piece of the Coronavirus

The SARS-CoV-2 virus is <u>studded with proteins</u> that it uses to enter human cells. These so-called spike proteins make a tempting target for potential <u>vaccines</u> and <u>treatments</u>.




The Oxford-AstraZeneca vaccine is based on the virus's <u>genetic</u> <u>instructions</u> for building the spike protein. But unlike the <u>Pfizer-</u><u>BioNTech</u> and <u>Moderna</u> vaccines, which store the instructions in single-stranded RNA, the Oxford vaccine uses double-stranded DNA.



## Astra Zeneca









### **mRNA** vaccines




Diagram: Callaway, E. (2020). The race for coronavirus vaccines: a graphical guide. *Nature*, <u>https://www.nature.com/articles/d41586-020-01221-y</u> Image from the Noun Project



### How mRNA COVID-19 Vaccines Work

#### Understanding the virus that causes COVID-19.

Coronaviruses, like the one that causes COVID-19, are named for the crown-like spikes on their surface, called **spike proteins**. These **spike proteins** are ideal targets for vaccines.

#### What is mRNA?

Messenger RNA, or mRNA, is genetic material that tells your body how to make proteins.

#### What is in the vaccine?

The vaccine is made of mRNA wrapped in a coating that makes delivery easy and keeps the body from damaging it.

#### How does the vaccine work?

The mRNA in the vaccine teaches your cells how to make copies of the **spike protein**. If you are exposed to the real virus later, your body will recognize it and know how to fight it off. TAUATIN TAUATIN When your body responds to the vaccine, it can sometimes cause a mild fever, headache. The vaccine DOES NOT contain ANY virus, so it cannot give you COVID-19. or chills. This is completely normal and a sign that the vaccine is working. It cannot change your DNA in any way 11111 Antibody After the mRNA delivers the instructions, your cells break it down and get rid of it.



# Ingredients



#### What's in the Pfizer jab?

- Nucleoside-modified messenger RNA — **active ingredient**
- ((4
  - hydroxybutyl)azanediyl)bis(hexane-6,1-diyl) bis(2-hexyldecanoate) (ALC-0315) — **lipid casing**
- 2-[(polyethylene glycol)-2000] N,N-ditetradecylacetamide
   (ALC-0159) lipid casing
- Distearoylphosphatidylcholine (DSPC) — lipid casing
- Cholesterol lipid casing
- Potassium chloride **salt**
- Monobasic potassium phosphate — salt
- Sodium chloride salt
- Dibasic sodium phosphate dihydrate — salt
- Sucrose sugar



Water for injections


#### What's in the AstraZeneca jab?

- Recombinant, replicationdeficient chimpanzee adenovirus vector — active ingredient
- Histidine amino acid
- Histidine hydrochloride monohydrate — amino acid salt
- Sodium chloride salt
- Magnesium chloride hexahydrate — salt
- Disodium edetate (EDTA) salt
- Sucrose sugar
- Ethanol absolute alcohol
- Polysorbate 80 surfactant
- Water

# R

#### Vaccine safety evaluation

Safety is considered at every phase of vaccine discovery and development. Upon licensure, vaccines enter phase 4, whereby surveillance approaches by regulators, such as the U.S. Food and Drug Administration (FDA), monitor potential vaccine side effects.







# Vaccine Safety





Monitoring Vaccine Safety

GOVERNMENT



53

#### National COVID-19 vaccine safety surveillance

Report No. 59 • 12 July 2021 Surveillance of COVID-19 vaccinations from 22 February 2021 Data provided by Vaxtracker, SmartVax and CVMS (data up to 12 July 2021 at 12 AM AEDT)

#### NO SAFETY SIGNALS DETECTED


2,284,635 surveys sent Australia wide\*

1,459,691 participants (63.9% response rate)

53.2% of participants reported no adverse event

46.8% of participants reported any adverse event

0.9% of participants reported visiting a doctor or emergency department



\*Surveys sent on Day 3 post vaccination. NOTE: Adverse events are self-reported, have not been clinically verified, and do not necessarily have a causal relationship with the vaccine.



#### Medium exposure risk in the Australian context

Scenario 2: Infection rate similar to second wave of COVID-19 in Victoria (275 infections per 100,000 people in a 16-week period)

#### For every 100,000 AstraZeneca vaccinations

Age	Potential harms Australian data as at 16 June 2021	Potential benefits	
18-29	1.9 blood clots (TTS) <sup>a</sup>	i	0.1 deaths prevented 1.3 ICU admissions prevented 10.6 hospitalisations prevented
30-39	1.6 blood clots (TTS) <sup>3</sup>	i	0.2 deaths prevented 1.2 ICU admissions prevented 10.7 hospitalisations prevented
40-49	5.0 blood clots (TTS) <sup>a</sup>		0.1 deaths prevented 2.6 ICU admissions prevented 16.7 hospitalisations prevented
50-59	2.7 blood clots (TTS)		<ol> <li>1.3 deaths prevented</li> <li>6.6 ICU admissions prevented</li> <li>24.3 hospitalisations prevented</li> </ol>
60-69	1.4 blood clots (TTS)		3.0 deaths prevented 7.0 ICU admissions prevented 30.4 hospitalisations prevented
70-79	1.8 blood clots (TTS)		21.4 deaths prevented 8.6 ICU admissions prevented 63.1 hospitalisations prevented
80+	1.9 blood clots (TTS)		183.6 deaths prevented
			5.2 ICU admissions prevented 260.5 hospitalisations prevented

TTS = thrombosis with thrombocytopenia syndrome. Includes probable and confirmed cases, and a range of health care presentations (including hospitalisations, ICU admissions and deaths).

 Estimates of risk are uncertain as rates are based on small numbers of vaccinations in people under 50 in Australia



Weighing up the potential benefits against risk of harm from COVID-19 Vaccine AstraZeneca (health.gov.au)



#### Table 2: Total confirmed and probable TTS cases to date by age and CDC classification

Age	Total cases	CDC classification†		
		Tier 1	Tier 2	Not classified
<30 years	1	-	1	-
30-39	1	1	-	-
40-49	4	4	-	-
50-59	22	10	6	6
60-69	15	4	5	6
70-79	21	7	5	9
80+	11	3	4	5
All ages	76 (36 men, 40 women)	29	21	26





### Table 3: Time to onset, treatment and outcomes for TTS cases\*

Time to onset/ diagnosis (days)	Median (range)	12 (1-54)
Treated in ICU	At any point	22
	Currently	6
Outcome	Discharged	52
	In hospital	22
	Fatal	2
		-



### Astra Zeneca can be given to people with history of Blood Clots



### AZ Vaccine for.....

- The risk of TTS is not likely to be increased in people with the following conditions, and people in these groups can receive <u>COVID-19 Vaccine</u> <u>AstraZeneca</u>:
  - History of blood clots in typical sites
  - Increased clotting tendency that is not immune mediated
  - Family history of blood clots
  - · History of ischaemic heart disease or stroke
  - Current or past thrombocytopenia (low platelet count)
  - Those receiving anticoagulation therapy



# Heuristics




- Understanding the mental shortcuts people make and the values they bring to weighing risks
- Heuristics to process risk information. These are mental shortcuts that allow them to make rapid judgements when dealing with large volumes of information.<sup>12</sup>
- Some people anticipate negative emotions because of a decision and thus avoid taking that course ("anticipated regret")
- People prefer to accept an outcome from doing nothing (not getting vaccinated) than an outcome from doing something (vaccinating) ("omission bias"),
- Avoid taking risks when the outcome is uncertain ("ambiguity aversion").



# Vaccine hesitancy



Hé important people feel respected, even when you don't agree with them. Itisten to what they're saying. Decurious. Not to Come across as patronising.







"The vaccines arrived so fast. How do we know they're safe ?"

Covid-19 vaccines went through the same safety checks as other vaccines. Rather than the science being sped up, the administrative and funding processes have been fast-tracked.



How to talk to friends and family feeling unsure about COVID-19 vaccines - ABC News

# Does vaccine stop transmission?



### Impact of vaccination on household transmission of SARS-COV-2 in England

A large study of COVID-19 transmission involving more than 365,000 households with a mix of vaccinated and unvaccinated members

Conclusions Both reduce likelihood of household transmission by 40-50% from individuals diagnosed with COVID-19 after vaccination.

35bf4bb1-6ade-d3eb-a39e-9c9b25a8122a (khub.net)

### nature medicine

# Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

Researchers identified nearly 5,000 cases of breakthrough infection in previously vaccinated people

Determined how much virus was present in their nose swabs.

Compared to unvaccinated people, the amount of virus detected was significantly lower in those who got vaccinated.

